1 |
Engelfriet P, Meijboom F, Boersma E, Tijssen J, Mulder B. Repaired and open atrial septal defects type II in adulthood: An epidemiological study of a large European cohort. Int J Cardiol 2008;126:379-85
DOI
ScienceOn
|
2 |
Engelfriet PM, Duffels MG, Moller T, Boersma E, Tijssen JG, Thaulow E, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007;93:682-7
DOI
PUBMED
|
3 |
Lee JE, Hillier SC, Knoderer CA. Use of sildenafil to facilitate weaning from inhaled nitric oxide in chilren with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 2008;23:329-34
DOI
ScienceOn
|
4 |
Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 2004;102:139-53
DOI
ScienceOn
|
5 |
Kim DK, Kim HK, Lim JA, Jeong SM, Jang SW, Yun IJ. Perioperative combined use of sildenafil and inhaled iloprost for moderate portopulmonary hypertension in a petient undergoing liver trasplantation - A case report-. Korean J Anesthesiol 2008;54:102-8
DOI
ScienceOn
|
6 |
Jung JW. Pulmonary arterial hypertension of congenital heart disease: from reversible pulmonary hypertension to Eisenmenger syndrome. Korean Circ J 2007;37:287-97
DOI
ScienceOn
|
7 |
Chang WH, Oh TY, Bae SI. Surgical Treatment of Atrial Septal Defect in adult. Korean J Thorac Cardiovasc Surg 1998;31:770-5
|
8 |
Kim JH, Lee KC, Chang YJ, Lim YT, Park JC, Cho YL. Inhaled nitric oxide as a therapy for pulmonary hypertension after operation for congenital heart disease. Korean J Anesthesiol 1999;37:1084-8
|
9 |
Winterhalter M, Simon A, Fischer S, Rahe-Meyer N, Chamtzidou N, Hecker H, et al. Comparison of inhaled iloprost and nitric oxide in patents with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth 2008;22:406-13
DOI
ScienceOn
|
10 |
Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with 'irreversible' pulmonary hypertensive arteriopathy. Int J Cardiol 2006;110:104-7
DOI
ScienceOn
|
11 |
Frost AE, Quinones MA, Zoghbi WA, Noon GP. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005;24:501-3
DOI
ScienceOn
|
12 |
Goldsmith DR, Wagstaff AJ. Inhaled iloprost: in primary pulmonary hypertension. Drugs 2004;64:763-73
DOI
ScienceOn
|
13 |
Viswanathan S, Kumar RK. Assessment of operability of congenital cardiac shunts with increased pulmonary vascular resistance. Catheter Cardiovasc Interv 2008;71:665-70
DOI
ScienceOn
|
14 |
Bratel T, Laqerstrand L, Brodin LA, Nowak J, Randmaa I. Ventilation/perfusion ratios in pulmonary arterial hypertension: effects of IV and inhaled prostacyclin derivatives. Chest 2005;128:615S-6S
PUBMED
|
15 |
Roques F, Nashef P, Michel E. Risk factors and outcome in European cardiac surgery: Analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:816-23
DOI
ScienceOn
|
16 |
Kim KB, Choi JS. Treatment of pulmonary hypertensive crisis using ECMO. Korean J Thorac Cardiovasc Surg 2002;35:664-7
|
17 |
Hoetzenecker K, Ankersmit HJ, Bonderman D, Hoetzenecker W, Seitelberger R, Klepetko W, et al. Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: A case report. J Thorac Cardiovasc Surg 2009;137:760-1
DOI
ScienceOn
|